Polymorphism in the IL-1β promoter is associated with IgG antibody response to circumsporozoite protein repeats of Plasmodium vivax.
Sign Up to like & getrecommendations! Published in 2020 at "Transactions of the Royal Society of Tropical Medicine and Hygiene"
DOI: 10.1093/trstmh/traa055
Abstract: BACKGROUND It is well established that infection by Plasmodium vivax is a result of host-parasite interactions. In the present study, association with the IL1/IL2 cytokine profiles, anticircumsporozoite protein antibody levels and parasitic loads was evaluated… read more here.
Keywords: circumsporozoite protein; antibody; vivax; plasmodium vivax ... See more keywords
Abstract 3675: Novel immune oncology strategy for targeted cytotoxic lymphocyte activation
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3675
Abstract: High-dose interleukin 2 (IL2) therapy was the first FDA-approved immunotherapy, and still has an exceptionally high true long-term cure rate for metastatic cancer. However, IL2 therapy has fallen out of favor due to systemic toxicity… read more here.
Keywords: therapy; oncology; omcp mutil2; mutil2 ... See more keywords
Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro
Sign Up to like & getrecommendations! Published in 2020 at "Bioengineering"
DOI: 10.3390/bioengineering7020059
Abstract: High-dose recombinant interleukin 2 (IL2) therapy has been shown to be successful in renal cell carcinoma and metastatic melanoma. However, systemic administration of high doses of IL2 can be toxic, causing capillary leakage syndrome and… read more here.
Keywords: bfp; hadscs il2; proliferation; hadscs ... See more keywords